In order to deliver quality study results and deliver on the pace of rapid innovation in the biopharma pipeline, drug developers need access to a proven, versatile protein quantification solution. In today's webinar, we'll discuss the new Worldwide Clinical Trials - SISCAPA partnership, which now offers sponsors compelling new assay development options.
Dr. Keller has a Ph.D. in analytical chemistry with a focus on mass spectrometry that she earned at the University of Texas at Austin. She has 20 years’ experience with qualitative and quantitative LC-MS applications. She is currently the head of Worldwide’s method development and validation group, which is based at the company’s bioanalytical laboratory in Austin, Texas.
Dr. Razavi obtained his B.Sc. in microbiology and his Ph.D. in Biochemistry from the University of Victoria with a focus on clinical proteomics. In his role as Director of Lab Operations, Morty has designed a fully automated SISCAPA workflow suitable for high throughput clinical settings that is compatible with whole blood, plasma, serum and dried blood spot specimens. His primary current focus is to develop diagnostic panels for longitudinal monitoring of health and disease using a single drop of blood. Morty believes that improved, individualized diagnostics will allow personalized medicine to reach its full potential and become widely accessible as a result of his work.
